Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUATRO: cabotegravir plus rilpivirine ultra-long-acting versus long-acting in virologically suppressed adults and adolescents with HIV
2024-518511-19-00Phase 3Authorised
- Sponsor
- ViiV Healthcare
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Planned start Aug 2026; status: authorised.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-518511-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518511-19-00.